2

ABSTRACT
The stromal compartments of hematopoietic organs; e.g., spleen, are known to influence the viability and growth of diseased hematopoietic progenitors. Here we have used Friend Murine Leukemia Virus (F-MuLV)-induced erythroleukemia to investigate factors of the splenic microenvironment that may make it fertile for the expansion and survival of malignant erythroblasts. We found that splenectomized, erythroleukemic mice exhibited extended survival compared to age-matched, sham controls. In vitro, the proliferation of primary erythroleukemic cells co-cultured with leukemic-derived splenic adherent cells or their conditioned media was found to be significantly higher than that observed in co-cultures with healthy-derived adherent splenic cells. Cytokine protein arrays revealed that F-MuLV-infected splenocytes secreted elevated levels of IL-6, VEGF-A, MCP-5, sTNFR1, IL-12p70, TNF-α and IL-2 over normal splenocytes.
Medium supplemented with both VEGF-A and MCP-5 could sustain proliferation of primary erythroleukemic cells in vitro and significant proliferative suppression was observed upon addition of neutralizing antibodies to either of these factors. Furthermore, in vivo administration of a neutralizing antibody to VEGF-A extended survival times of erythroleukemic mice in comparison to controls. These findings suggest that VEGF-A and MCP-5 are potentially pivotal paracrine mediators occurring within the diseased splenic microenvironment capable of promoting disease acceleration and expansion of erythroleukemic blasts.
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INTRODUCTION
Solid tumors can be viewed as abnormal organs comprised of three general cell types; tumor cells, tumour-associated endothelium and the stroma (for reviews see 1, 2 ).
The latter two serve to nourish and support the growing tumor cell mass, respectively.
Similarly, the stroma of hematopoietic organs is known to support the processes of normal and malignant hematopoiesis; i.e., 'liquid' tumors or leukemias 3, 4 . In both cases, support cells are essential for tumor growth and metastasis. However, the changes occurring in their associated endothelial and stromal cells that accelerate the disease process are poorly characterized.
A number of hematologic malignancies including chronic lymphocytic leukemia (CLL), marginal zone non-Hodgkin's lymphoma (NHL), hairy-cell leukemia (HCL), and chronic myelogenous leukemia (CML) display varying propensities for pathologic enlargement of the spleen (splenomegaly) [5] [6] [7] . Thus, splenic involvement appears to be stage-specific for each type of disease and generally considered to take place during the mid to late stages. Particularly for CML, splenomegaly is evident during accelerated disease and blast crisis 8 . Surgical intervention (splenectomy) is typically reserved for patients who are experiencing extreme discomfort or who may benefit from a laparotomy if such a procedure is thought to be useful in governing the therapeutic strategy 8 . These clinical observations suggest mechanistic growth response elements contributed by the spleen, which remain rather enigmatic.
F-MuLV-induced erythroleukemia has been used for decades as a model for analyzing neoplastic transformation, leukemia progression, genetic susceptibility to cancer, and more recently, erythroid differentiation 9, 10 .
It is well established that
following inoculation of neonates of susceptible murine strains with F-MuLV, infected erythroblasts depart the bone marrow and sequester within the spleen 11 , followed by the development of foci over the following two weeks 12 . It has been previously reported that the spleen plays a role in the susceptibility and resistance of the host to Friend Virus infection from the polycythemia variant of Friend virus (FVP) 13 .
Recent studies have shown that several factors are important for leukemic proliferation, some of which are produced by the bone marrow stroma [14] [15] [16] . For example, leukemic cells usually differentiate in the presence of erythropoietin (EPO). However, if such cells are co-cultured with bone marrow stroma in the presence of EPO, they are prevented from undergoing terminal differentiation 14 . These results suggest that factors in the bone marrow stroma can block EPO-induced terminal differentiation of erythroblasts. Therefore, since splenic involvement is prevalent in several hematologic disorders of mouse and man, we decided in the current study to investigate whether the splenic stroma affects the erythroleukemic overgrowth modeled by Friend Disease.
Here we have studied the changes occurring in the microenvironment of the spleen, which could potentially accelerate the pathological course of Friend Disease; a model known to exhibit considerable splenic involvement. We report here that among several pertinent angiogenesis/inflammatory cytokines assayed in an in vitro system obtained from F-MuLV-infected splenocytes, VEGF-A and MCP-5 appear to be key players contributing to the accelerated overgrowth of erythroleukemic cells. We also show that erythroleukemic mice treated with a neutralizing antibody against VEGF-A survive longer than controls. Hence, the splenic stroma of erythroleukemic mice produces pro-angiogenic / inflammatory factors that contribute to the progression of the disease. 
MATERIALS AND METHODS
Murine Splenectomy
Viral lysates of the replication competent NB-tropic F-MuLV were prepared through repeated culturing of the fibroblastic, Clone-B cell line in minimum essential medium-alpha medium (αMEM) (Gibco) supplemented with 10% fetal bovine serum (Gibco) and penicillin/streptomycin at 1000U/mL (Gibco). Four week-old BALB/c mice infected at birth with F-MuLV were divided into two groups; splenectomized group and sham controls. All procedures were conducted according to institutional guidelines.
Briefly, mice were anaesthetized and injected with the analgesic, buprenorphine. A 1cm midline incision through the skin and musculature was made just below the sternum followed by exposure of the spleen. It was then gently retracted, freed and removed by cauterization. Musculature and subcutaneous tissues were closed by absorbable sutures and metal wound clips, respectively. Similarly, sham control mice underwent this operative procedure only with spleens remaining intact.
Tumor isolation and in vitro expansion of healthy-and leukemic-derived splenic adherent cells and primary erythroleukemic cells
Briefly, BALB/c neonates (n=3) were infected with the replication competent helper virus, F-MuLV one-day post birth as to induce erythroleukemia (Friend Disease) (for review see 10 ). Age-matched, non-infected littermates (n=3) served as controls. After 9 weeks, leukemic mice with palpable spleens and decreased hematocrit values, both measured to ascertain leukemic burden (volume expansion) were sampled. At this point the spleen is highly enriched (>90%) for leukemic erythroblasts. Mice were anaesthetized For personal use only. on October 2, 2017. by guest www.bloodjournal.org From 6 with 4% isoflurane and spleens were excised and placed in sterile 1X phosphate buffered saline (PBS), followed by mechanical homogenization using a mortar and pestle and two washes in 1X PBS. Cells were plated in αMEM medium containing 10% fetal bovine serum (FBS), 10 ng/mL stem cell factor (SCF), 1 U/mL erythropoietin (EPO) and 10 ng/mL epidermal growth factor (EGF), and allowed to expand for a period of 3-4 days until adherent and suspension cells were easily discernible. At this time, 50% of the media was exchanged with fresh media every 3 days. After 3-5 such cycles, suspension cells were then considered as primary erythroleukemic cells. Such procedures were carried out according to a previously described method so as to obtain splenic adherent cells in culture 17 . Following separation of suspension from adherent cells, erythroleukemic cells were centrifuged at 200g for 5 min. These cells were then plated and cultured in fresh medium, medium derived from adherent cell line cultures or similarly with the addition of various cytokines and neutralizing antibodies as described below.
Detection of viral integration into erythroleukemic splenocytes
Genomic DNA was extracted from cultured cells using DNA mini kit (Qiagen). PCR was performed with 2µl of DNA, 2U Taq DNA polymerase (Invitrogen), 10mM dNTP, 100pg of each primer, and the provided PCR reaction buffer. The primers were designed from the Friend virus env that provides a product of about 500bp. Sense: 5'-CCTTGGCTATCCGGTTTACA-3'. Anti-sense: 5'-GGACAGGGTCAGCTTGTGTT-3'.
The reaction was allowed to proceed at 94°C for 1 min, at 55°C for 45 sec, and at 72°C 
Proliferation Assays
Unless indicated otherwise, primary erythroleukemic cell lines were cultured at a starting density of 1 x 10 4 cells/mL in conditioned αMEM medium (10% FBS, 10 ng/mL SCF, 1 U/mL EPO and 10 ng/mL EGF). Cells were allowed to grow over a period of 72 hours, during which time cell counts and viability were assessed every 24 hours by the method of trypan blue exclusion (Gibco) utilizing a hemocytometer. Similarly, these experiments were repeated and results confirmed using the method of AlamarBlue TM reduction assay (BioSource international) 19 .
In some experiments erythroleukemic (suspension) cells were co-cultured with adherent cells to ascertain that stimulatory 
Protein Cytokine Antibody Array
Starvation medium (2% FBS, 100 ng/mL SCF, 1 U/mL EPO and 10 ng/mL EGF) was pre-cultured for 24 hours with murine leukemic-derived splenic adherent cells 
Qualitative and quantitative assessment of the splenic microvasculature
Spleens from healthy and erythroleukemic mice were harvested and fixed in 10% buffered formalin and paraffin sections were prepared, followed by immunostaining as a previously described protocol 21 with the following modifications. Purified rat anti-mouse CD144 (VE-cadherin) (Santa Cruz biotechnologies) was incubated with 1:200 dilution in antibody diluting buffer (Dako) for 2 hours at room temperature. After several washes with PBS, a secondary antibody, anti-rat-IgG (Jackson ImmunoResearch Laboratories), was incubated for 30 min at room temperature followed by streptavidin/biotin labeling using HistoStain TM SP Kit (Zymed). For quantification purposes the immunostained sections of both healthy and leukemic spleens were scanned and assessed for vessel area using Adobe Photoshop 6 software (Adobe Systems Incorporated). The vessel areas were
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Microvascular corrosion casting
Microvascular casting was conducted as previously described 22 . Briefly, mice were anesthetized and injected i.v. with 10,000 U/kg heparin via the tail vein, following vascular rinsing with lactated Ringer's solution plus 1 U/ml heparin until clear of red blood cells. Mice were then perfused with Baston's no.17 casting polymer, a mixture of 6.5ml monomer-base, 1.5ml catalyst, and 0.2ml promoter solution. After polymerization, the animal was digested with a 30% potassium hydroxide solution. Spleen vessels casts were removed rinsed in distilled water, and dried. Then, samples were mounted on specimen holders and sputter-coated with gold in an argon atmosphere, and examined by scanning electron microscope.
Statistical analysis
Comparison of growth kinetics within a given experiment was conducted using repeated Student's t-Test for one and two populations with significance values of P<0.05.
One-way ANOVAs were conducted in similar fashion with significance values of P<0.05.
RESULTS
Splenectomy extends survival of erythroleukemic mice.
In order to test whether removal of the spleen during early disease offered mice with Friend Disease a survival benefit, 4 week-old erythroleukemic mice were either splenectomized (n=10) or underwent a sham procedure (n=10), and monitored weekly.
Moribund mice were monitored closely and sacrificed according to institutional guidelines over the following weeks. Mice were sacrificed when either exhibiting severe anemia or considerable abdominal swelling due to severe splenomegaly. As depicted in 
LDSAC, but not HDSAC, drives the expansion of erythroleukemic blasts in vitro.
Since stromal cell compartments are known to support and promote the growth of cancers in general, both in solid and liquid tumors 2, 4 , we asked whether they also contribute, at least in part, to the ability of the spleen to drive the overgrowth of a 
LDSAC-conditioned medium potentiates expansion of erythroleukemic blasts in vitro.
Several studies have shown that malignant hematopoiesis is regulated by both autocrine and paracrine signaling loops 23, 24 . To delineate the mode by which splenic stroma promotes F-MuLV induced erythroleukemia, we collected media from cultures equal in number for LDSAC, HDSAC, bone marrow stroma or NIH-3T3 cells and tested their affects on the growth of primary erythroleukemic cells. The results in Figure 2B indicate that only when primary erythroleukemic cells were grown with LDSAC-
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conditioned medium, did they show an increased proliferation rate in vitro (P<0.05).
These results suggest that an intricate role of paracrine signaling in erythroleukemic cell expansion is present within the spleen.
F-MuLV-infected mice exhibit integration into the genome of LDSAC.
A recent study has reported that in addition to the infection of erythroblasts, B and T cells are also susceptible target cells of Friend virus during late-stage disease. These virus-positive cells are highly populated in the bone marrow and spleen 25 . Prior to conducting further experiments, we set out to ascertain whether the stromal compartment of the spleen was genetically altered due to retroviral insertional mutagenesis by FMuLV, hence, conceivably attributing to phenotypic alterations. Similar processes have also been described in systems to obtain immortalized fibroblasts 26 . As seen in Figure 3 , viral env sequence PCR product was observed in LDSAC, but not in HDSAC.
Comparisons were made using HB-60 erythroleukemic cells 27 as a positive control and NIH-3T3 fibroblasts as a negative control. Our results, therefore, indicate that the nature of Friend virus integration is not only into erythroblasts, although the primary cause of death is consistently erythroleukemia.
LDSACs produce factors with proangiogenic and inflammatory activities.
In order to ascertain that the composition of the LDSAC-derived medium was indeed responsible for the differences observed in the proliferative capacity of erythroleukemic cells, 22 different cytokines and growth factors were assayed by antibody arrays. HDSAC and LDSAC were cultured in starvation medium for 24 hours.
For
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The medium was then collected and screened for the presence of cytokines according to Materials and Methods. The array signals along with a graphical interpretation of the normalized values are depicted in Figure 4 . In the HDSAC-conditioned medium, only IL-4, MCP-1 and IL-12 cytokines were overexpressed (>50% normalization) whereas several additional cytokines, namely IL-6, VEGF-A, MCP-5 and sTNFR1 were expressed overabundantly in LDSAC-conditioned medium. In addition, there was a presence of elevated expression of IL-12p70, TNF-α and IL-2 (P<0.05). These observations indicate that the splenic stroma of erythroleukemic mice secretes proangiogenic and inflammatory cytokines, some of which may be essential for the leukomogenic process.
Combination of VEGF-A/MCP-5 induces erythroleukemic expansion in vitro
without further potentiation in the presence of IL-6 or TNF-α.
Next, we sought to determine which of the cytokines that were overexpressed by LDSACs could potentiate erythroleukemic cell proliferation, hence, those factors that could be implicated as mediators of paracrine induction within the spleen. To verify these conclusions, neutralizing antibodies against VEGF-A and MCP-5 were added to primary erythroleukemic cells cultured with LDSAC conditioned media.
Both αMCP-5 and αVEGF-A alone, or in combination inhibit growth of erythroleukemic cells, when compared to LDSAC conditioned medium alone (P<0.05). However, the most effective suppression is observed using αVEGF-A, as a single agent, or in combination with MCP-5, although not reaching significance ( Figure 5B ). The addition of a neutralizing antibody against TNF-α was also tested to rule out other potential mediators that seemed to be deregulated when comparing LDSAC and HDSAC cultures.
However, the growth kinetics of primary cells was not altered in its presence. Thus, our results suggest that both VEGF-A-and MCP-5-mediated paracrine signaling are the most biologically relevant mediators of diseased potentiation within the spleens of erythroleukemic mice.
Elevated numbers of endothelial cells comprise the LDSAC over HDSAC
Since LDSAC secretes a 15 fold higher concentration of VEGF-A than HDSAC, and given the knowledge of its potent angiogenic properties, we compared the percentage of endothelial cells between HDSAC and LDSAC. For this approach, LDSAC and HDSAC populations from both early and late stages of erythroleukemia were tested for the presence of endothelial markers, flk-1 and CD13, and the hematopoietic marker CD45 according to Materials and Methods and previously described methodologies 20, 28 . The results in Figure 6 show that in the later stage (9 weeks post tumor induction) HDSAC In order to test whether our in vitro findings can still be carried out in erythroleukemic mice in vivo, we tested whether treating diseased mice with a neutralizing antibody against VEGF-A, can decelerate tumor growth kinetics, hence extending survival. For this approach, 5 week old erythroleukemic mice were divided into three groups: 1. a group treated with 50µg/mouse of a neutralizing antibody against VEGF-A, twice weekly for two weeks according to a previous study 18 ; 2. a group treated with goat IgG (control) antibody administered at the same concentration schedule as that of the first group; and 3. a control group similarly administered with PBS (n=5/group).
The results in Figure 7 show that mice treated with VEGF-A neutralizing antibody, exhibit a moderately extended median survival time of 15 days over control mice (88 versus 74, respectively). Mice treated with goat IgG exhibit no significant difference from the untreated control group (data not shown). These results suggest that indeed, erythroleukemic mice treated with a VEGF-A neutralizing antibody exhibit a prolonged survival, despite a short-term administration of this anti-angiogenic agent.
DISCUSSION
In the present study we demonstrate a role of the splenic microenvironment in sustaining and promoting a hematologic malignancy, modeled by Friend Disease.
Adherent cells generated from spleens of diseased, but not healthy mice were found to sustain the proliferation of erythroleukemic blasts in vitro. This observation indicated that the physiology of splenic cells in erythroleukemic mice was conditioned to provide a supporting microenvironment for the progression of the disease. Indeed, in assessing the profile of cytokines inherent to the pathological spleen, an upregulation of several cytokines in cultures of erythroleukemic adherent cells was demonstrated. Further analyses revealed that two of these cytokines, namely VEGF-A and MCP-5, were mandatory for the proliferation of erythroleukemic blasts in vitro. This conclusion is based on two experimental outcomes: First, medium supplemented with both VEGF-A and MCP-5 was sufficient to provide growth of erythroleukemic blasts, similar to that observed with LDSACs or their conditioned medium. Second, neutralizing antibodies to either VEGF-A or MCP-5 blocked the ability of LDSAC conditioned media to promote erythroleukemia blast overgrowth. We suggest that during the development of erythroleukemia, the spleen becomes a preferential site for propagation of malignant blasts since its stromal compartments provides an essential paracrine-potentiated overgrowth via the secretion of primarily VEGF-A and MCP-5. Indeed, when we administered a neutralizing antibody against VEGF-A to erythroleukemic mice, we found that they exhibited prolonged survival.
In retrospect, it is not surprising that VEGF-A constitutes a major microenvironmental factor promoting leukemogenesis. The role of pro-angiogenesis-
factors in the progression of several solid tumors is well established. Only recently, however, has the angiogenic response in leukemia been uncovered. Following the discovery of increased microvessel density within the bone marrow of pediatric and adult cancer patients with distinct types of leukemia 29, 30 , there has been increasing evidence to suggest that angiogenesis and leukemia progress in a synchronized manner, primarily by the production of several key angiogenic mediators (for review see 31 ).
Indeed, of these several pro-angiogenic mediators currently known, VEGF-A continues to be extensively investigated as it has been associated with several hematologic malignancies 31 . Recent evidence suggests that both autocrine and paracrine signaling loops exist among malignant blasts and endothelial cells (both cell autonomous and nonautonomous); these involve primarily VEGF signaling following the binding of its receptor, flk-1, to facilitate aggressive expansion of the disease 24, 32 . As such, this information suggests that a conducive organ microenvironment is an essential component for the survival and expansion of the tumors (leukemia), albeit in a stage-and subtypedependant manner. Our work reinforces recent findings by showing that VEGF-A is a mediator of leukemic cell expansion, at least in a paracrine manner 24 . However, in addition to this we have also observed that the expansion of erythroleukemic cells is also dependant on the presence of the inflammatory mediator, MCP-5.
We have observed that MCP-5 is one of the primary contributors to the proliferation of erythroleukemic blasts, and is highly overexpressed in LDSAC culture. In this work, we demonstrated that anti-MCP-5 and anti-VEGF-A neutralizing antibodies as single agents or in combination suppressed the proliferation of erythroleukemic cells.
However, the VEGF-A neutralizing antibody exhibited the greatest impact overall. Significance between splenectomy and sham groups was calculated using Mann-Whitney U test with 2-sided P values and significant differences reflecting a P<0.05. (6) and 1kbp (7) ladder was extracted. Friend virus env primers were used to amplify the integration site of the virus' env using the conditioned described in Materials and Methods. 
